Standigm ASK review
A target-identification platform that pairs disease-specific predictions with evidence to explore.
Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026
Standigm ASK helps drug discovery researchers identify and prioritize novel targets for a selected disease or phenotype. It is aimed at teams that need evidence and biological context around target candidates, rather than software for designing molecules or repurposing existing drugs. Standigm describes the platform as AI-aided, combining curated public data and publication-derived information with knowledge-graph deep learning, natural-language processing, metabolic models, and network analysis. Its focus is target discovery, so it fits research teams whose immediate question is which disease-associated targets merit further investigation.
The product’s breadth is concentrated on target evidence. It supports genotype–phenotype prediction based on genome-scale metabolic models and random-walk modeling across protein-interaction networks and omics data. Researchers can interactively explore prioritization evidence, browse databases, and examine pathways, disease–target paths, and gene expression. Those views give users several routes to inspect predicted target relationships rather than treating a candidate list as the entire output. Customer-specific database modifications and integration of in-house data may also help teams bring internal research context into the workflow. ASK is available through the web and uses cloud deployment.
Access is sales-led: the vendor invites prospective users to contact it for a trial version, while its plans are not presented as public self-service tiers. That makes it sensible for teams prepared to discuss fit and access with Standigm, but less suited to buyers who need to evaluate published plan prices before engaging. Choose ASK when disease- or phenotype-driven target prioritization and evidence exploration are central needs, particularly when internal data could be relevant. Teams seeking molecule design or drug repurposing should look elsewhere, since those are outside ASK’s documented target-identification scope.
Standigm ASK pros and cons
- Where it wins
- Combines literature-derived and curated public evidence for target prioritization
- Explores target evidence through pathways, disease–target paths, and gene expression
- Can integrate in-house data and customer-specific database modifications
- Where it doesn't
- Focused on target identification, not molecule design or drug repurposing
- Cloud deployment may not suit teams requiring another deployment model
- Access is sales-led rather than based on published self-service plans
Standigm ASK fact sheet, pricing and score →
Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. Bought places stand at the number bought; this page and our disclosure say so. Paying vendors may get a fuller, more detailed review from our editors, and that review can change their score. How we rank.
Last updated · How we research and update